Evan Wu, MD
Internal Medicine · Fort Lauderdale, FLNPI 1891149126
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Johnson & Johnson at 37.6% of the total. 2025 is the largest year on record at $60,128, more than ten times the $160 reported in 2020. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 155 payments — averaging $734.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$43K
- Boehringer Ingelheim$27K
- Jazz Pharmaceuticals Inc.$13K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- AstraZeneca$4K
- Amgen$4K
- plus $16K from 23 others
Across 3 payments — averaging $16,043 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirati Therapeutics, Inc.$48K
What the payments were for
- Consulting fees$33,22729%
- Speaking & faculty fees$64,69357%
- Travel & lodging$11,39010%
- Food & beverage$4,5874%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 55 | $42,811 |
| Boehringer Ingelheim | 15 | $27,422 |
| Jazz Pharmaceuticals Inc. | 9 | $12,877 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $6,218 |
| AstraZeneca | 11 | $4,428 |
| Amgen | 4 | $4,197 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,922 |
| AbbVie | 2 | $2,400 |
| Daiichi Sankyo Inc. | 8 | $2,346 |
| Springworks Therapeutics, Inc. | 4 | $2,198 |
| Fosun Pharma USA Inc. | 3 | $2,003 |
| Janssen Scientific Affairs, LLC | 5 | $1,950 |
| Genentech USA, Inc. | 1 | $1,070 |
| Novocure Inc. | 3 | $224 |
| AVEO Pharmaceuticals, Inc. | 3 | $205 |
| Mirati Therapeutics, Inc. | 6 | $120 |
| Regeneron Healthcare Solutions, Inc. | 1 | $99 |
| Sanofi | 2 | $92 |
| Gilead | 1 | $68 |
| Merck | 2 | $54 |
| Pfizer | 2 | $41 |
| Astellas Pharma US Inc | 2 | $31 |
| Rigel Pharmaceuticals, Inc. | 1 | $27 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Bayer | 1 | $14 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$113,897 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 229 | $3,885,325 |
| LenvimaLenvatinib Mesylate | 21 | $511,056 |
| AlecensaAlectinib Hcl | 19 | $339,404 |
| KrazatiAdagrasib | 12 | $264,944 |
| EliquisApixaban | 18 | $13,588 |
| Dexamethasone | 68 | $3,000 |
| Ondansetron Hcl | 74 | $1,371 |
| Prochlorperazine Maleate | 70 | $891 |
| Betamethasone Dipropionate | 20 | $850 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 35 | $381 |
| Gabapentin | 23 | $374 |
| LoperamideLoperamide Hcl | 14 | $340 |
| Oxycodone Hcl | 19 | $300 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $267 |
| Folic Acid | 28 | $254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $4,428 | $3,885,325229 claims |
| Genentech USA, Inc.Alecensa | $1,070 | $339,40419 claims |
| Mirati Therapeutics, Inc.Krazati | $120 | $264,94412 claims |
| PfizerEliquis | $41 | $13,58818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Fort Lauderdale
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Sheetal SharmaFort Lauderdale$184K
- Haytham ElgammalMiami$2.2M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.